145 related articles for article (PubMed ID: 28247997)
1. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.
Huet S; Szafer-Glusman E; Tesson B; Xerri L; Fairbrother WJ; Mukhyala K; Bolen C; Punnoose E; Tonon L; Chassagne-Clément C; Feugier P; Viari A; Jardin F; Salles G; Sujobert P
Am J Hematol; 2017 Jun; 92(6):515-519. PubMed ID: 28247997
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
3. Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: correlation with clinicopathologic features in 48 patients.
Yanai S; Nakamura S; Takeshita M; Fujita K; Hirahashi M; Kawasaki K; Kurahara K; Sakai Y; Matsumoto T
Cancer; 2011 Jun; 117(11):2467-77. PubMed ID: 24048795
[TBL] [Abstract][Full Text] [Related]
4. Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Correia C; Maurer MJ; McDonough SJ; Schneider PA; Ross PE; Novak AJ; Feldman AL; Cerhan JR; Slager SL; Witzig TE; Eckloff BW; Li H; Nowakowski GS; Kaufmann SH
Blood Cancer J; 2023 May; 13(1):81. PubMed ID: 37193683
[TBL] [Abstract][Full Text] [Related]
5. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
Correia C; Schneider PA; Dai H; Dogan A; Maurer MJ; Church AK; Novak AJ; Feldman AL; Wu X; Ding H; Meng XW; Cerhan JR; Slager SL; Macon WR; Habermann TM; Karp JE; Gore SD; Kay NE; Jelinek DF; Witzig TE; Nowakowski GS; Kaufmann SH
Blood; 2015 Jan; 125(4):658-67. PubMed ID: 25452615
[TBL] [Abstract][Full Text] [Related]
6. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
Burkhard R; Bhagat G; Cogliatti SB; Rossi D; Gaidano G; Pasqualucci L; Novak U
Hematol Oncol; 2015 Mar; 33(1):23-30. PubMed ID: 24496723
[TBL] [Abstract][Full Text] [Related]
7. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
8. Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.
Tsukamoto T; Kiyota M; Kawata E; Uoshima N; Tatekawa S; Chinen Y; Nagoshi H; Mizutani S; Shimura Y; Yamamoto-Sugitani M; Kobayashi T; Horiike S; Yasukawa S; Yanagisawa A; Taniwaki M; Kuroda J
Int J Hematol; 2017 May; 105(5):658-667. PubMed ID: 27995457
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
10. A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.
Janikova A; Mareckova A; Dvorakova D; Bortlicek Z; Tichy B; Navratil M; Kral Z; Pospisilova S; Mayer J
Exp Hematol; 2012 Jul; 40(7):528-539.e4. PubMed ID: 22381682
[TBL] [Abstract][Full Text] [Related]
11. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
12. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
van Oers MH; Tönnissen E; Van Glabbeke M; Giurgea L; Jansen JH; Klasa R; Marcus RE; Wolf M; Kimby E; Vranovsky A; Holte H; Hagenbeek A; van der Reijden BA
J Clin Oncol; 2010 May; 28(13):2246-52. PubMed ID: 20368567
[TBL] [Abstract][Full Text] [Related]
13. Partial lack of BCL2 in follicular lymphoma: An unusual immunohistochemical staining pattern explained by ongoing BCL2 mutation.
van den Brand M; Garcia-Garcia M; Mathijssen JJ; Colomo L; Groenen PJ; Serrano S; van Krieken JH
Pathol Res Pract; 2016 Feb; 212(2):148-50. PubMed ID: 26725534
[TBL] [Abstract][Full Text] [Related]
14. Follicular lymphoma presenting follicular papules in the skin: A case report.
Ozaki S; Funasaka Y; Shimizu A; Kawarasaki M; Kanzaki A; Matano Y; Futagami A; Yamaguchi H; Sugisaki Y; Saeki H
J Dermatol; 2017 Jan; 44(1):111-113. PubMed ID: 27153936
[No Abstract] [Full Text] [Related]
15. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
16. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
[TBL] [Abstract][Full Text] [Related]
17. [Follicular non-Hodgkin lymphomas and minimal residual disease].
Bruno S
Medicina (B Aires); 2000; 60 Suppl 2():77-82. PubMed ID: 11188937
[TBL] [Abstract][Full Text] [Related]
18. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.
Leich E; Hoster E; Wartenberg M; Unterhalt M; Siebert R; Koch K; Klapper W; Engelhard M; Puppe B; Horn H; Staiger AM; Stuhlmann-Laeisz C; Bernd HW; Feller AC; Hummel M; Lenze D; Stein H; Hartmann S; Hansmann ML; Möller P; Hiddemann W; Dreyling M; Ott G; Rosenwald A;
Leukemia; 2016 Apr; 30(4):854-60. PubMed ID: 26621338
[TBL] [Abstract][Full Text] [Related]
19. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions.
Pham-Ledard A; Cowppli-Bony A; Doussau A; Prochazkova-Carlotti M; Laharanne E; Jouary T; Belaud-Rotureau MA; Vergier B; Merlio JP; Beylot-Barry M
Am J Clin Pathol; 2015 Mar; 143(3):362-73. PubMed ID: 25696794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
